Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Intensity Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- 0 vs. Q3 2024
- Shares held
- 2.72M
- +980.1K (+56.3%) vs. Q3 2024
- Total value
- $4.79M
- −$1.86M (−27.9%) vs. Q3 2024
- New holders
- 3
- 4 more added
- Sold out
- 3
- 5 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INTS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $4.79M |
| Q1 2026 | 14 | $1.06M |
| Q4 2025 | 35 | $1.58M |
| Q3 2025 | 26 | $721.2K |
| Q2 2025 | 27 | $606.6K |
| Q1 2025 | 21 | $5.10M |
| Q4 2024 | 20 | $4.79M |
| Q3 2024 | 20 | $6.65M |
| Q2 2024 | 23 | $8.23M |
| Q1 2024 | 18 | $8.49M |
| Q4 2023 | 17 | $4.39M |
| Q3 2023 | 10 | $1.19M |
| Q2 2023 | 2 | $170.2K |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Intensity Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 17 | $30 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 50 | $88 | 0.00% | +1+2.0% | Added |
| Morgan Stanley | 500 | $880 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,648 | $4.66K | 0.00% | +1,479+126.5% | Added |
| UBS Group AG | 3,021 | $5.32K | 0.00% | −17,588−85.3% | Reduced |
| Stonebridge Financial Group, LLC | 8,301 | $14.6K | 0.00% | +8,301 | New |
| State Street Corp | 14,500 | $25.7K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 14,964 | $26.5K | 0.00% | +14,964 | New |
| Lakeview Capital Partners, LLC | 17,420 | $30.7K | 0.01% | 00.0% | Unchanged |
| GTS Securities LLC | 19,030 | $33.7K | 0.00% | −18,258−49.0% | Reduced |
| Mesirow Financial Investment Management, Inc. | 20,000 | $35.2K | 0.00% | −24,177−54.7% | Reduced |
| BlackRock, Inc. | 22,252 | $39.2K | 0.00% | +139+0.6% | Added |
| One Charles Private Wealth Services, LLC | 31,800 | $56.0K | 0.02% | 00.0% | Unchanged |
| Blair William & Co | 37,805 | $66.5K | 0.00% | 00.0% | Unchanged |
| Sigma Planning Corp | 54,837 | $96.5K | 0.00% | +7,093+14.9% | Added |
| Geode Capital Management, LLC | 64,349 | $113.9K | 0.00% | 00.0% | Unchanged |
| Brown Advisory Inc | 130,072 | $228.9K | 0.00% | −18,037−12.2% | Reduced |
| Vanguard Group Inc | 208,886 | $369.7K | 0.00% | 00.0% | Unchanged |
| Sapient Capital LLC | 942,841 | $1.66M | 0.03% | −67,912−6.7% | Reduced |
| Armistice Capital, LLC | 1,126,868 | $1.98M | 0.05% | +1,126,868 | New |
| Sentinus, LLC | 0 | $0 | 0.00% | −18,918−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −10,414−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −3,450−100.0% | Sold out |